This immunotoxin was achieved by conjugating/fusing the Anti-CSPG4 scFv to saporin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to tumor cells and enters cells by receptor-mediated endocytosis. Upon release of the conjugate from endosomes, the saporin toxin catalytically renders the large subunit ribosomes unable to bind the elongation factors and inhibits protein synthesis. It was designed for treatment of glioblastoma multiforme (GBM).
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.